[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.
In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.
[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.
The combination resulted in durable response in many patients.
[Journal of Hepatocellular Carcinoma] In this review, the authors discuss the use of imaging techniques and radiological biomarkers to monitor treatment response in patients with advanced HCC undergoing antiangiogenic therapy, a key to decisions on whether to continue treatment or initiate second-line therapy.
Retrospective analysis of older Hispanic patients with HCC treated with sorafenib have better survival than their younger counterparts, but more data are needed.
[Journal of Hepatocellular Carcinoma] A case of rare site HCC metastasis to the nail bed highlights the disease course and prognosis for patients with this rare clinical occurrence.
In a registry study, patients with HBV or HCV who began low-dose aspirin had lower rates of HCC and 10-year liver-related mortality compared with nonusers.
Information on ITH can provide insight into the clonal evolutionary processes occurring within the tumor in response to prior treatment.
The median change in HCC tumor size between responders and nonresponders was statistically significant.
